TIANDA PHARMA (00455) announced its interim results for 2025. During the period, the group recorded revenue of HK$137 million, representing a decrease of 12.45% compared to the same period last year. The loss attributable to company shareholders was HK$33.237 million, expanding by 22.03% year-on-year. Basic loss per share was HK$0.0155.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.